ArticleCureus2025
Quality of Life Assessment in Non-melanoma Skin Cancers and Comparison of the Quality of Life Between Psoriasis and Vitiligo Patients.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective Despite the increase in incidence of non-melanoma skin cancers (NMSC), deaths are relatively rare. The goal of treatment is to prevent the recurrence of the disease and to increase the quality of life (QoL). The QoL and the cost of treatment are becoming more important treatment goals, as nowadays NMSC are rarely life-threatening. This study aims to assess and compare the QoL in patients with NMSC, psoriasis, and vitiligo using three validated QoL instruments. Methods A total of 150 patients were included in this study, with 50 patients each diagnosed with NMSC, psoriasis, and vitiligo. The QoL was assessed using the European Organization for Research and Treatment of Cancer Core QoL Questionnaire (EORTC QLQ-C30), the Dermatology Life Quality Index (DLQI), and the World Health Organization Quality of Life Scale Short Form (WHOQOL-BREF). Sociodemographic data and disease severity were also recorded. Results The study found that NMSC and psoriasis patients had similar QoL scores, with both groups showing more significant impairment in QoL than vitiligo patients. Psoriasis patients experienced greater deterioration in daily activities and personal relationships, while QoL in work, school, and treatment domains was worse in both NMSC and psoriasis patients compared to vitiligo patients. A negative correlation was observed between disease duration and the physical health domain subscale of the WHOQOL-BREF, as well as the work and school subscale of the DLQI, in vitiligo patients; and between disease duration and the work and school subscale of the DLQI in NMSC patients. Conclusion The findings underscore the significant impact of NMSC on patients' QoL, highlighting the importance of comprehensive management strategies in these conditions. The similarity in QoL scores obtained across all groups using DLQI and WHOQOL-BREF suggests that the WHOQOL-BREF, a general health QoL scale, can be effectively used alongside the DLQI, a dermatology-specific QoL scale, to assess QoL in dermatologic diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.